Karimi_2020_BMC.Chem_14_64

To discover multifunctional agents for the treatment of Alzheimer's disease (AD), a new series of 1,2,3-triazole-chromenone derivatives were designed and synthesized based on the multi target-directed ligands approach. The in vitro biological activities included acetylcholinesterase (AChE) and butyrylcholinesterase (BuChE) inhibition as well as anti-Abeta aggregation, neuroprotective effects, and metal-chelating properties. The results indicated a highly selective BuChE inhibitory activity with an IC(50) value of 21.71 M for compound 10h as the most potent compound. Besides, compound 10h could inhibit self-induced Abeta(1-42) aggregation and AChE-induced Abeta aggregation with 32.6% and 29.4% inhibition values, respectively. The Lineweaver-Burk plot and molecular modeling study showed that compound 10h targeted both the catalytic active site (CAS) and peripheral anionic site (PAS) of BuChE. It should be noted that compound 10h was able to chelate biometals. Thus, the designed scaffold could be considered as multifunctional agents in AD drug discovery developments.